Agilent Technologies, Inc. - Global Leader in Life Sciences, Diagnostics and Applied Chemic

Company Profile (Updated April 2026)

Agilent Technologies, Inc. is a global leader in life Sciences, diagnostics, and applied chemical markets, providing application-focused solutions that enAble scientists and researchers to advance scientific discovery and improve healthcare outcomes. Founded in 1999 as a spin-off from Hewlett-Packard Company and headquartered in Santa Clara, California, USA, Agilent has established itself as one of the world's premier analytical instrumentation companies.

The company operates through a global network of 28 manufacturing sites and serves customers in over 110 countries through direct sales, service teams, and strategic distribution partnerships. With approximately 18,000 employees worldwide, Agilent combines deep scientific expertise with advanced digital capabilities to deliver innovative products and services across pharmaceutical, biotechnology, chemical, environmental, food safety, and clinical diagnostics markets.

Corporate History & Leadership

Founded: 1999 (spin-off from Hewlett-Packard)
   Headquarters: 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA
   CEO & President: Padraig McDonnell (appointed February 2024)
   Company Type: Public Company (NYSE: A)
   Employees: ~18,000 worldwide
   Manufacturing Sites: 28 facilities globally
   Fiscal Year 2025 Revenue: $6.95 billion (+6.7% reported growth; +4.9% core growth)
   FY2025 Non-GAAP EPS: $5.59
   FY2025 GAAP EPS: $4.57
   FY2026 Revenue Guidance: $7.3-7.5 billion (+5.5-7.5% reported; +4-6% core)
   FY2026 Non-GAAP EPS Guidance: $5.90-6.04
   Website: www.agilent.com

Under CEO Padraig McDonnell's leadership since February 2024, Agilent has accelerated its Ignite operating system initiative—a comprehensive transformation program designed to enhance operating efficiency, digital capabilities, and customer experience. The company has successfully navigated macroeconomic headwinds including tariffs and China market challenges while maintaining robust growth in key segments.

Business Segment Structure

Effective Q1 2025, Agilent reorganized into three strategic business segments to better align with customer needs and market opportunities:

Life Sciences and Diagnostics Markets Group (LDG)

Q4 FY2025 Revenue: $755 million (+15% reported; +11% core)
   Operating Margin: 22.7%
   Focus Areas: Pharmaceutical and biopharmaceutical markets, clinical diagnostics, pathology solutions
   Key Products: Liquid chromatography (LC), mass spectrometry (LC/MS), cell analysis, genomics, companion diagnostics, pathology instrumentation

LDG serves pharmaceutical and biotechnology companies developing innovative therapeutics, including GLP-1 weight management drugs where Agilent generated approximately $130 million in FY2025 revenue (split between analytical tools and CDMO services). The segment includes the BioVectra CDMO (Contract Development and Manufacturing Organization) specializing in synthetic peptide manufacturing.

Agilent CrossLab Group (ACG)

Q4 FY2025 Revenue: $755 million (+7% reported; +6% core)
   Operating Margin: 32.5%
   Focus Areas: Consumables, services, enterprise solutions
   Key Offerings: Chromatography consumables (columns, supplies), instrument services, training, enterprise service contracts, digital solutions

ACG provides the recurring revenue Foundation for Agilent through consumables and services, with strong attACHment rates to installed instruments. The segment launched the Altura Ultra Inert Columns in 2025, driving over 30% growth in bio-column revenue. Enterprise services now represent approximately 10% of total services revenue, growing at low double-digit CAGR through embedded on-site support and digital solutions.

Applied Markets Group (AMG)

Q4 FY2025 Revenue: $351 million (+4% reported; +3% core)
   Operating Margin: 24.7%
   Focus Areas: Chemical and energy industries, environmental testing, food safety, forensics, academia
   Key Products: Gas chromatography (GC), atomic spectroscopy, molecular spectroscopy, mass spectrometry

AMG delivered strong performance in advanced materials with 20% growth in the materials subsegment driven by semiconductor onshoring trends. The segment serves environmental, food safety, and chemical applications with comprehensive analytical workflows.

Financial Performance (FY2025 & Q1 2026)

Fiscal Year 2025 (Ended October 31, 2025)

- Total Revenue: $6.95 billion (+6.7% reported; +4.9% core)

- Q4 FY2025 Revenue: $1.86 billion (+9.4% reported; +7.2% core), exceeding guidance

- Q4 GAAP Net Income: $434 million ($1.53 per share)

- Q4 Non-GAAP EPS: $1.59 (vs. $1.46 in Q4 2024)

- Operating Cash Flow: $268 million in Q1 2026; capital expenditures of $93 million

- Capital Deployment: $152 million share repurchases; $72 million dividends paid in Q1 2026

Q1 Fiscal Year 2026 (Ended January 31, 2026)

- Revenue: $1.80 billion (+7.0% reported; +4.4% core)

- Non-GAAP EPS: $1.36 (+4% year-over-year), adjusted for $10 million weather impact would have exceeded guidance midpoint

- Operating Margin: 24.6% (down 50 bps YoY due to tariffs and normalized performance-based pay)

- Instrument Book-to-Bill: At or above 1 for eighth consecutive quarter

End-Market Performance (Q1 2026)

- Pharmaceutical: +7% (excluding academia/government, instruments grew mid-single digits)

- Biotechnology: Double-digit growth; BioVectra CDMO added ~$25 million in Q4 2025

- GLP-1 Business: +50% in Q1 2026 (7% analytical lab; 120% CDMO)

- Chemicals & Advanced Materials: +9% overall; +20% in materials subsegment (semiconductor onshoring)

- Diagnostics & Clinical: +7%

- Environmental & Forensics: Flat

- Food: -4%

- Academia & Government: -8% (continued funding softness)

- china: +6% (minor government stimulus impact; baseline ~$300 million per quarter)

Strategic Growth Drivers

Instrument Replacement Cycles:

- LC (Liquid Chromatography) Replacement: Infinity 3 HPLC platform driving double-digit growth; high single-digit global LC growth with market share gains

- GC (Gas Chromatography) Replacement: Low single-digit growth in Q1 2026; mid-single-digit ex-China; ~100 bps lift expected during replacement cycle

- LC/MS (Mass Spectrometry): Single quad family growth >40% in Q1 2026 led by Pro IQ LCMS adoption; 50% of top 20 biopharma companies ordered Altura columns post-October 2025 launch

Pharma Reshoring Opportunity:

Management estimates a $1 billion addressable market opportunity through 2030 from anticipated pharmaceutical manufacturing reshoring to the United States. First orders expected late in FY2026 with revenue recognition beginning in FY2027 (ending October 31, 2027). This represents potential upside to current guidance.

Ignite Operating System:

Agilent's comprehensive transformation program delivered nearly 200 basis points of pricing benefit in Q1 2026. Ignite drives efficiency, digital order growth, and cost savings through AI-powered tools, process optimization, and enhanced commercial execution.

Recent Strategic Developments (2025-2026)

Regulatory & Diagnostic Achievements:

- February 2026: FDA approval of Agilent's PD-L1 companion diagnostic test alongside Merck's Keytruda for platinum-resistant ovarian cancer—seventh FDA-approved companion diagnostic use for the Agilent PD-L1 assay

Strategic Acquisition:

- March 9, 2026: Announced $950 million all-cash acquisition of Biocare Medical (immunohistochemistry, ISH, FISH pathology solutions) from Excellere Partners and GHO Capital Partners; Biocare generated $90 million revenue in 2025 with double-digit growth; expected to close Q4 2026

Product Innovation:

- Altura Columns: Ultra-inert bio-columns driving >30% growth in bio-column segment

- S540MD Digital Slide Scanning System: New pathology imaging platform

- Raman Insight BRT Series: Secured $9 million TSA (Transportation Security Administration) contract

Sustainability & Operations:

- CARESAFE IV Sets: Launched September 2024—first robust PVC-free and DEHP-free IV administration portfolio (B. Braun collaboration)

- ISO 27001 Certification: Achieved September 2024 for information security management

Geographic Presence

Americas: Headquarters in Santa Clara, CA; major operations in Massachusetts, Delaware, Texas; +1% growth in Q1 2026 (impacted by winter storm)

Europe: +4% growth in Q1 2026; transient tariff discussions caused some customer purchasing delays

Asia-Pacific: Strongest growth region; +13% rest of Asia; China +6% with $300 million quarterly baseline

Manufacturing Locations: USA (multiple states), Germany (Tuttlingen—Aesculap surgical instruments), Malaysia (Penang), China (Suzhou), France, UK, Italy, Japan, Australia

2026 Outlook & Strategic Vision

FY2026 Full-Year Guidance:

- Revenue: $7.30-7.50 billion (core growth 4-6%; reported growth 5.5-7.5% including 1.5% currency tailwind)

- Non-GAAP EPS: $5.90-6.04 (raised from $5.86-6.00 due to favorable currency; +5.5-8% growth)

- Operating Margin: +75 basis points expansion at midpoint (tariff mitigation and Ignite benefits weighted to second half)

- Operating Cash Flow: $1.6-1.7 billion

- Capital Expenditures: ~$500 million

Q2 FY2026 Guidance:

- Revenue: $1.79-1.82 billion (core growth 4-5.5%; ~3% currency tailwind; includes recovery of Q1 weather-delayed shipments)

- Non-GAAP EPS: $1.39-1.42 (+6-8% growth)

- Operating Margin: +100 basis points sequential improvement vs. Q1

Strategic Priorities:

1. Advance Ignite Operating System: Continue digital transformation, pricing optimization, and operational efficiency

2. Capture Replacement Cycle: Maximize Infinity 3 LC and GC replacement opportunities; sustain LCMS momentum

3. Expand Recurring Revenue: Grow consumables and services attachment; scale enterprise services to >10% of services

4. Strategic M&A: Integrate Biocare Medical; pursue financially attractive, strategically aligned acquisition opportunities

5. Pharma Reshoring: Position to capture $1 billion 2030 opportunity from US manufacturing onshoring

6. Innovation Pipeline: Launch S540MD, Raman Insight BRT, and next-generation IHC portfolio through Biocare integration

Contact Information

Global Headquarters

Company: Agilent Technologies, Inc.
   Address: 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA
   Phone: +1 (877) 424-4536 (US/Canada)
   Website: www.agilent.com
   Investor Relations: investors.agilent.com

Regional Headquarters

Americas: Santa Clara, CA, USA; Wilmington, DE, USA
   Europe: Waldbronn, Germany; Cheadle, UK
   Asia-Pacific: Singapore; Tokyo, Japan; Beijing, China

Keywords: Agilent Technologies,安捷伦科技,NYSE A,life sciences,diagnostics,applied markets,Padraig McDonnell,FY2025,FY2026,Biocare Medical acquisition,March 9 2026,$6.95 billion revenue,$7.3-7.5 billion guidance,Ignite operating system,Infinity 3 HPLC,Pro IQ LCMS,Altura columns,GLP-1,pharma reshoring,Life Sciences and Diagnostics Markets Group,Agilent CrossLab Group,Applied Markets Group,BioVectra,companion diagnostic,PD-L1,18,000 employees,28 manufacturing sites,$5.59 Non-GAAP EPS